Company inception

Became eligible for tax incentives programs under the Act for the Development of Biotech and New Pharmaceutical Industry, Minister of Economic Affairs

Turned public in compliance with regulations governed by Securities and Futures Bureau of Financial Supervisory Committee

Stock trading on Emerging Stock Board of Taipei Exchange, stock ticker: 6499

U.S. Food and Drug Administration 510(k) clearance for ClickClean™ (LAP-A01) Laparoscope Lens Shield Device

Successful First-in-Man Studies for XPro™ (IVC-C01, now Cross-Seal™) Large Bore Suture-Mediated Vascular Closure Device

Publicly listed (IPO) on Taipei Exchange, stock ticker: 6499

U.S. Food and Drug Administration 510(k) clearance for AbClose™(LAP-C01) Trocar Wound Closure Device

Invested in Prodeon to develop the Mercury Project (URO-T01) for treatment of Benign Prostatic Hyperplasia (BPH)

Invested in Delta Asia International Co. to enrich manufacturing capability

Entered into an Asset Purchase Agreement with Terumo for XPro™ System (IVC-C01, now Cross-Seal™) Large Bore Suture-Mediated Vascular Closure Device

Received FDA 510(k) Clearance for the PUMA™ System

Successful secondary public offering (SPO) at Taipei Exchange

Delta Asia International Co. publicly listed (IPO) on Taipei Exchange, stock ticker: 6762

Announced positive interim clinical results of 32 patients for XFLO™ Minimally Invasive BPH Treatment Device

Cross-SealTM received PMA Approvable Letter from U.S. FDA

The group has established a new business entity and has successively acquired MediBalloon and Second Source Medical to expand its business in medical device contract development and manufacturing (CDMO).

Urocross™ Expander system – treatment for lower urinary tract symptoms (LUTS) associated with benign Prostatic Hyperplasia (BPH) (URO-T01) was approved by the US FDA for Investigational Device Exemption (IDE) and successfully complete first randomization.

Cross-SealTM announced the completion of US FDA cGMP on-site inspection

Duett received U.S. FDA clearance for its first-in-human clinical trial

Medeon wins U.S. FDA PMA for Cross-Seal™

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett™